IRVINE, California—Beta Bionics Inc., a diabetes management solutions and stage medical device company, announced the launch of its “iLet" Bionic Pancreas, which uses 15-day sensor continuous glucose monitoring (CGM) system “FreeStyle Libre 3 Plus” by Abbott, a medical devices and health care company.
This bionic pancreas product is an autonomous insulin delivery system that aims to improve diabetes management and reduce the burden on patients, caregivers and physicians. The iLet connects to the Abbott sensor, which aims to help the iLet calculate insulin dose with readings every minute. Rather than requiring users to count carbohydrates or calculate insulin corrections throughout the day, the iLet aims to determine all insulin doses and only requires the user’s weight in order to begin usage.
“Beta Bionics continues to move at lightning speed to bring these enhancements to our userbase,” said Sean Saint, CEO of Beta Bionics. “With our recent launch of the bionic circle remote monitoring app, our latest updates to the iLet app and (the) launch of the iLet integration with Abbott’s FreeStyle Libre 3 Plus sensor, we are focused on providing major product enhancements to make diabetes management even easier for our users and their families.”
The company said the launch of this product seeks to offer users a new way to manage their type one diabetes. Additionally, platform users will be able to access supplies with pay-as-you-go model offered by Beta Bionics. By updating the iLet app and software, users are offered the choice of integrated CGM, such as the FreeStyle Libre 3 Plus or Dexcom CGM, upon setting up a new sensor.
